#liver cancer

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

Smoking cessation, moderate drinking, a healthy diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer.

Hepatitis B and C, non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease are the main causes of liver cancer and cirrhosis.

Women with a history of the malignancy also survive longer than men after receiving a liver transplant.

Successful treatment with direct-acting antivirals prolonged survival by 18 months.

People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.

This finding from a recent study applies to those who do not have cirrhosis when they are treated for the virus.

A new classification system may more accurately reflect liver-related death trends in the United States.

Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.

People with liver cirrhosis often have substantial financial burden that interferes with their care.

The tool relies on 14 clinical variables, such as liver enzymes, body mass index, triglycerides, height and sex.

This could provide a safer, simpler alternative to the invasive surgical biopsies used to diagnosis liver disease.

October is Liver Cancer Awareness Month.

Those diagnosed with liver cancer after an HCV cure had a 66% lower risk of death.

In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.

Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.

The International Liver Conference will be held in April 2020.